Armoda

Armoda is indicated to improve wakefulness in adult patients with-
Obstructive sleep apnea (OSA)
Narcolepsy
Shift work disorder (SWD)

Dosage & Administration

Adults
:
Obstructive Sleep Apnea & Narcolepsy: 150 mg to 250 mg as a single dose in the morning.
Shift Work Disorder: 150 mg as a single dose approximately 1 hour prior to the start of work shift.
Children
: Safety and effectiveness in pediatric patients less than 17 years of age have not been established.
Elderly
: In elderly patients, elimination of Armodafinil and its metabolites may be reduced as a consequence of aging. Therefore, consideration should be given to the use of lower doses and close monitoring in this population.

The most common side effects of Armoda are serious rash, including Stevens-Johnson syndrome, angioedema and anaphylaxis reactions, multi-organ hypersensitivity reactions, persistent sleepiness, psychiatric symptoms and some cardiovascular events.

Patients should be cautioned about operating an automobile or other hazardous machinery until it is reasonably certain that Armoda therapy will not adversely affect their ability to engage in such activities. Caution should be taken in treating patients with a history of psychosis, depression or mania. Discontinuation of treatment should be considered if psychiatric symptoms develop. Increased monitoring of heart rate and blood pressure should be exercised. Caution should be exercised when prescribing Armoda to patients with known cardiovascular disease.

Armodafinil is an indirect dopamine receptor agonist. This is the R-enantiomer of Modafinil which is a 1:1 mixture of the R- and S-enantiomers. Armodafinil binds to the dopamine transporter and inhibits dopamine reuptake. As a result, increases neuronal activity in the hypothalamus, enhances activity in hypothalamic wakefulness center (TMN, tuberomammillary nucleus) within the hypothalamic sleep wake switch.